Axsome Therapeutics, listed as NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company recently reported its earnings for February 23, 2026, with an EPS of -$0.56, which was better than the expected -$0.70. This positive surprise in earnings per share indicates that the company is performing better than analysts anticipated.
The company also reported a revenue of approximately $196 million, surpassing the estimated $193.3 million. This increase in revenue is a positive sign for Axsome, as it suggests that the company is successfully growing its sales. The price-to-sales ratio of 16.50 indicates that investors are willing to pay $16.50 for every dollar of sales, reflecting confidence in the company's future growth potential.
Despite the positive earnings report, Axsome has a negative P/E ratio of -40.04, indicating that the company is not currently profitable. The earnings yield of -2.50% further emphasizes this lack of profitability. However, the company's current ratio of 1.57 suggests that it has a reasonable level of short-term liquidity to cover its current liabilities, which is a positive sign for its financial health.
Axsome's enterprise value to sales ratio is 16.31, similar to its price-to-sales ratio, indicating that the company's valuation is closely tied to its revenue. However, the enterprise value to operating cash flow ratio is significantly negative at -90.69, highlighting challenges in generating positive cash flow from operations. This could be a concern for investors, as it suggests that the company may struggle to fund its operations without external financing. The company's debt-to-equity ratio of 2.96 indicates a higher level of debt compared to equity, which could pose a risk if the company is unable to generate sufficient cash flow to service its debt.
